

G1:O,S

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 16:Atom 17:CLASS


```

L1            STRUCTURE   UPLOADED

$$\Rightarrow d$$

L1 HAS NO ANSWERS

L1	STR
----	-----



Structure attributes must be viewed using STN Express query preparation.

=> s ll ful

FULL SEARCH INITIATED 17:36:45 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 116 TO ITERATE

100.0% PROCESSED 116 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

L2 0 SEA SSS FUL L1

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY


TOTAL  
SESSION

FULL ESTIMATED COST

161.33

161.54

STN INTERNATIONAL LOGOFF AT 17:36:51 ON 20 JUN 2005



chain nodes :

7 8 9 10 11 12 16

ring nodes :

1 2 3 4 5 19

chain bonds :

1-10 3-7 7-8 8-9 8-11 10-16 11-12

ring bonds :

1-5 1-19 2-3 2-19 3-4 4-5

exact/norm bonds :

1-5 1-19 2-3 2-19 3-4 4-5 8-9 10-16 11-12

exact bonds :

1-10 3-7 7-8 8-11

isolated ring systems :

containing 1 :

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS


11:CLASS 12:CLASS 16:Atom 19:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 17:22:35 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 673 TO ITERATE


100.0% PROCESSED 673 ITERATIONS  
 SEARCH TIME: 00.00.01

0 ANSWERS

L2 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10-759562a.str



chain nodes :

8 9 10 11 12 13 17

ring nodes :

1 2 3 4 5 6

chain bonds :

1-11 4-8 8-9 9-10 9-12 11-17 12-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 11-17 12-13

exact bonds :

1-11 4-8 8-9 9-12

isolated ring systems :

containing 1 :

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS


11:CLASS 12:CLASS 13:CLASS 17:Atom

L3 STRUCTURE UPLOADED

=> d

L3 HAS NO ANSWERS

L3 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=&gt; s l3 ful

FULL SEARCH INITIATED 17:23:04 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 20207 TO ITERATE

100.0% PROCESSED 20207 ITERATIONS  
 SEARCH TIME: 00.00.01

82 ANSWERS

L4 82 SEA SSS FUL L3

=&gt; fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

322.23

322.44

FILE 'CAPLUS' ENTERED AT 17:23:08 ON 20 JUN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jun 2005 VOL 142 ISS 26

FILE LAST UPDATED: 19 Jun 2005 (20050619/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=&gt; s l4

L5 10 L4

=&gt; d ibib abs hitstr tot

L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:56606 CAPLUS

DOCUMENT NUMBER: 141:123628

TITLE:

INVENTOR(S):

Preparation of aryl/heteroaryl substituted  
imidazoquinolines as immunomodulators  
Hays, David S.; Niwas, Shri; Kshirsagar, Tushar;  
Ghosh, Tarun K.; Gupta, Shalley K.; Heppner, Philip  
D.; Merrill, Bryon A.; Bonk, Jason D.; Danielson,  
Michael E.; Gerster, John F.; Haraldson, Chad A.;  
Johannessen, Sarah C.; Kavanagh, Maureen A.;  
Lindstrom, Kyle J.; Prince, Ryan B.; Radmer, Matthew  
R.; Rice, Michael J.; Squire, David J.; Strong, Sarah  
A.; Wurst, Joshua R.

PATENT ASSIGNEE(S): 3M Innovative Properties Company, USA

SOURCE: PCT Int. Appl., 465 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058759	A1	20040715	WO 2003-US40373	20031218
WO 2004058759	C1	20050317		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG	US 2004147543	A1	20040729	US 2003-739787
PRIORITY APPL. INFO.:				US 2002-435889P
				US 2003-516331P
				P 20031218
				P 20021220
				P 20031031

OTHER SOURCE(S):

GI

MARPAT 141:123628



L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)



L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


AB Title compds. I (R = alkyl, alkoxy, OH, CF3; n = 0, 1; R1, R2 = H, non-interfering substituent; R3 = Ar2, aminosulfonylaryl, aminocarbonylaryl, etc.; Ar = aryl, heteroaryl; Z = bond, alkylene, alkenylene, alkynylene) which are immunomodulators, inducing cytokines biosynthesis, and inhibiting tumor necrosis factors biosynthesis, are prepared for example,  
 2-butyl-1-isobutyl-7-(thiophen-3-yl)-1H-imidazo[4,5-c]quinolin-4-amine was prepared in a multi-step synthesis starting from 3-bromoaniline, tri-tert-butyl orthoformate, and Meldrum's acid. I are useful in the treatment of viral and neoplastic diseases.

IT 723267-80-9P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of imidazoquinoline derivs. as immunomodulators for treatment of viral and antineoplastic diseases)

RN 723267-80-9 CAPLUS  
 CN 1-piperidineethanol, 4-[[4-amino-2-(ethoxymethyl)-7-(3-pyridinyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl]-α-(phenylmethoxy)methyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 723267-79-6  
 CMF C34 H40 N6 O3



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2

L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:349075 CAPLUS

DOCUMENT NUMBER: 134:348289

TITLE: Selective serotonin reuptake inhibitors for anxiolytics and antidepressants

INVENTOR(S): Takado, Toru; Masumoto, Shuji; Kojima, Atsushi

PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.

CODEN: JKKXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001131149	A2	20010515	JP 1999-316476	19991108
PRIORITY APPL. INFO.:			JP 1999-316476	19991108

OTHER SOURCE(S): MARPAT 134:348289

GI



AB The inhibitors comprise heterocyclic compds. I [Cyl = monocyclic aryl, dicyclic fused aromatic hydrocarbyl, fused aromatic heterocyclyl; Cy2 = (un)substituted aryl, aromatic heterocyclyl, cycloalkyl; Y1, Y2 = single bond, CH2, O; Y3 = (un)substituted alkylene; Y4 = (un)substituted alkylene, alkenylene, alkynylene; Y5 = single bond, O, S, NH; R1, R2 = H, substituent; R3, R4 = H, OH, alkyl; Q, Z = methine, N; n, m = 1-3], their prodrugs, or pharmaceutically acceptable salts are prepared  
 1-(2-bromo-5-methoxybenzyl)-4-(3-chloropropyl)piperazine was treated with 2-fluoro-3-methoxypiperidine in the presence of K2CO3 and KI in acetonitrile under reflux for 2 h to give 68%

1-(2-bromo-5-methoxybenzyl)-  
 4-[3-[(4-(2-fluoro-5-methoxybenzyl)piperidino)propyl]piperazine showing good [3H]citalopram binding inhibitory activity in vitro.

IT 339152-68-0P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)


(selective serotonin reuptake inhibitors for anxiolytics and antidepressants)

RN 339152-68-0 CAPLUS


CN 1-piperidineethanol, α-[(1H-indol-4-yloxy)methyl]-4-[3-[(2-naphthalenylmethyl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:98548 CAPLUS  
 DOCUMENT NUMBER: 132:151675  
 TITLE: Preparation of disubstituted maleimide compds. in medicinal utilization  
 INVENTOR(S): Inaba, Takashi; Tanaka, Masahiro; Sakoda, Kenji  
 PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan  
 SOURCE: PCT Int. Appl., 181 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006564	A1	20000210	WO 1999-JP4085	19990728
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2338866	AA	20000210	CA 1999-2338866	19990728
AU 9949299	A1	20000221	AU 1999-49299	19990728
JP 2000109479	A2	20000418	JP 1999-213248	19990728
EP 1120414	A1	20010801	EP 1999-933165	19990728
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 9912612	A	20011120	BR 1999-12612	19990728
NO 2001000487	A	20010328	NO 2001-487	20010129
PRIORITY APPL. INFO.:			JP 1998-215070	A 19980730
			WO 1999-JP4085	W 19990728
OTHER SOURCE(S):		MARPAT 132:151675		
GI				

L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



II

AB Title compds. [I; wherein R1 = H, alkyl; R2 = aryl, cycloalkyl, heterocycle; R3, R5, R6, R7 and R8 represent each hydrogen, halogeno, hydroxy, amino, alkyl or alkoxy; R4 = H, CH2CH2NR9R10; R9 = alkyl; R10 = arylalkyl, alkylamino, dialkylamino; R4 and R3 or R4 and R5 may form together a ring substituted by substituted alkyl], pharmaceutically acceptable salts, and medicinal compds. as protein kinase (PKC)  $\beta$ -inhibitors and used as efficacious and safe remedies and preventives for diseases caused by PKC such as complications of diabetes. The title compound II was prepared

IT 257878-98-1P

RL: SAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of disubstituted maleimide compds. in medicinal utilization)

RN 257878-98-1 CAPLUS

CN 1H-Pyrrole-2,5-dione,


3-[1-[[1-(2,3-dihydroxypropyl)-4-piperidinyl]methyl]-1H-indol-3-yl]-4-(phenylamino)- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1993:530901 CAPLUS  
 DOCUMENT NUMBER: 119:130901  
 TITLE: Synthesis and anti-HIV activity of a series of 2-indolinones and related analogs  
 AUTHOR(S): Smallheer, J. M.; Otto, M. J.; Amaral-Ly, C. A.; Earl, R. A.; Myers, M. J.; Pennev, P.; Montefiori, D. C.; Wuonola, M. A.  
 CORPORATE SOURCE: Du Pont Merck Pharm. Co., Wilmington, DE, 19880, USA  
 SOURCE: Antiviral Chemistry & Chemotherapy (1993), 4(1), 27-39  
 DOCUMENT TYPE: CODEN: ACCHEH; ISSN: 0956-3202  
 LANGUAGE: Journal  
 GI: English



AB A novel series of 2-indolinones with in vitro anti-HIV (human immunodeficiency virus) activity is described. Two structurally related compounds, 3,3-(4-N-methyl-1,2,5,6-tetrahydropyridylmethyl)-1-phenyl-2-indolinone (I), and its 4-N-methylpiperidylmethyl analog (II), formed the basis of a structure-activity study. The synthesis of approx. 50 analogs and their resp. activities vs. HIV are presented. Both I and 2 were effective inhibitors of HIV(IIb) in cell protection assays with values of 4.4 and 14.9  $\mu$ M (2.2 and 7.9  $\mu$ g mL<sup>-1</sup>), resp. In the same concentration range, 1 and 2 also inhibit syncytia formation. These compounds represent a novel class of anti-HIV agents which appear to act by inhibiting virus-dependent cell fusion.

IT 147947-58-07  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 147947-58-8 CAPLUS  
 CN 2H-Indol-2-one, 3-[[1-(2,3-dihydroxypropyl)-4-piperidinyl]methyl]-1,3-dihydro-1-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




not  
 mono

L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1993:495325 CAPLUS  
 DOCUMENT NUMBER: 119:95325  
 TITLE: Preparation of 3-methyleneisindolin-1-one derivatives  
 INVENTOR(S): Mohri, Shinichiro; Obase, Hiroyuki; Ikeda, Junichi; Kubo, Kazuhiro; Mori, Akihisa; Ishii, Akio  
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 185 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9217448	A1	19921015	WO 1992-JP246	19920302
W: CA, JP, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE PRIORITY APPLN. INFO.: JP 1991-68379 A 19910401				

OTHER SOURCE(S): MARPAT 119:95325  
 GI




AB The title compounds [I; A, B = CH, N; R1, R2 = alkyl; R3, R4 = halo, alkoxy, etc.; X = (substituted) heterocyclyl; Y = (CH2)1-4] are prepared A solution of Me2CHCH2MgBr in THF was added to a solution of imide II in THF with stirring at room temperature under Ar, 4 N HCl was added with stirring, followed by H2O and 10 N NaOH, and the mixture was extracted with EtOAc to give 50% III, which as a phosphate salt showed min. ED of 6.3 mg/kg p.o. for cerebral protection in mice.

IT 149261-70-12

L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as ischemic cerebral disease drug)  
 RN 149261-70-1 CAPLUS  
 CN Acetic acid, [2-[[1-(3-(4-fluorophenoxy)-2-hydroxypropyl)-4-piperidinyl]methyl]-2,3-dihydro-3-oxo-1H-isindol-1-ylidene]-, ethyl ester, monohydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



not  
 mono



L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1988:437821 CAPLUS

DOCUMENT NUMBER: 109:37821

TITLE: Preparation of 4-[(bicyclic heterocyclyl)methyl]piperidines and analogs as antihistaminics

INVENTOR(S): Janssens, Frans E.; Kennis, Ludo E. J.; Hens, Jozef F.; Torremans, Joseph L. G.; Diels, Gaston S. M.

PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.

SOURCE: U.S., 59 pp. Cont.-in-part of U.S. Ser. No. 571,135, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4695575	A	19870922	US 1985-747754	19850624
ES 539281	A1	19870616	ES 1984-539281	19841231
AU 8537364	A1	19850912	AU 1985-37364	19850107
AU 573673	B2	19880616		
CA 1259609	A1	19890919	CA 1985-471589	19850107
DK 8500089	A	19850710	DK 1985-89	19850108
FI 8500079	A	19850710	FI 1985-79	19850108
FI 83867	B	19910531		
FI 83867	C	19910910		
NO 8500085	A	19850710	NO 1985-85	19850108
NO 160849	B	19890227		
NO 160849	C	19890607		
JP 60185777	A2	19850921	JP 1985-479	19850108
JP 07068240	B4	19950726		
HU 36471	A2	19850930	HU 1985-61	19850108
HU 200338	B	19900528		
ZA 8500187	A	19850827	ZA 1985-187	19850108
RO 90622	B3	19861210	RO 1985-117252	19850108
SU 1396964	A3	19880515	SU 1985-3836858	19850108
IL 74018	A1	19880831	IL 1985-74018	19850108
PL 145710	B1	19881031	PL 1985-251488	19850109
US 4839374	A	19890613	US 1987-94987	19870910
PRIORITY APPLN. INFO.:			US 1984-569369	A2 19840109
			US 1984-671135	A2 19841113
			US 1985-747754	A3 19850624

OTHER SOURCE(S): CASREACT 109:37821

GI

L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB The title compds. (I; 3 of A1-A4 = (un)substituted CH, the 4th = N, (un)substituted CH; B = CH<sub>2</sub>, O, SO, SO<sub>2</sub>; R = substituted C1-6 alkyl, alkoxy, alkylthio, amino, pyrrolidinyl, piperidinyl, hexahydroazepinyl, etc.; R1 = H, alkyl, cycloalkyl, (un)substituted aryl, heteroaryl, (hetero)aralkyl; R2 = H, alkyl and their stereoisomers and acid salts were prepared as antihistaminics and serotonin antagonists. 1-[(4-fluorophenyl)methyl]-2-(4-piperidinylmethyl)-1H-benzimidazol-5-ol and PhSCH<sub>2</sub>CH<sub>2</sub>Br were refluxed 2 h in Me<sub>2</sub>CHCH<sub>2</sub>COMe containing Na<sub>2</sub>CO<sub>3</sub> to give 27.8% benzimidazole derivative (II). I inhibited compound 48/80-induced lethality in rats, caused by histamine release, with ED<sub>50</sub> of 0.005-0.16 mg/kg s.c. or orally. I also inhibited gastric lesions caused by simultaneous release of serotonin.

IT 99958-99-3P  
RL: SAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as antihistaminic)


RN 99958-99-3 CAPLUS  
CN 1-Piperidineethanol, 4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]methyl]-α-[[2-naphthalenyloxy)methyl]-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 99958-98-2

CMF C33 H34 F N3 O2

L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2

CRN 144-62-7

CMF C2 H2 O4



L5 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:213320 CAPLUS

DOCUMENT NUMBER: 104:213320

TITLE: Dental cements containing vinyl monomers

INVENTOR(S): Shimakawa, Shuzo; Ooyagi, Shigehiro

PATENT ASSIGNEE(S): Nisshin Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKKOAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61027907	A2	19860207	JP 1984-150313	19840718
JP 62051927	B4	19871102		

PRIORITY APPLN. INFO.: JP 1984-150313 19840718

GI



AB Dental cements contain the monomer I (R = H or Me) and polymerization catalyst.

Thus, 1,3-bis(4-piperidyl-N-2-hydroxypropylmethacryl)propane (II) was prepared by treating glycidyl methacrylate with

1,3-di(4-pyridyl)propane. A

dental cement contained 5 g II and 3 g poly(Me methacrylate) powder (containing 2% benzoyl peroxide). A strong adhesion to dental alloys and porcelain was demonstrated.


IT 102254-32-0P

RL: PREP (Preparation) (preparation of, for dental cement composition)

RN 102254-32-0 CAPLUS

CN 2-Propenoic acid, 2-methyl-, 1,3-propanediylbis[4,1-piperidinediyl(2-hydroxy-3,1-propanediyl)] ester (9CI) (CA INDEX NAME)

L5 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L5 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986.68861 CAPLUS

DOCUMENT NUMBER: 104:68861

TITLE: (Piperidinylmethyl)- and (piperidinylalkoxy)benzimidazole

INVENTOR(S): s and -imidazopyridines  
Josephine: Janssens, Frans Eduard; Kennis, Ludo Edmond

Hens, Jozef Francis; Torremans, Joseph Leo G.; Diels, Gaston Stanislas M.

PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.

SOURCE: Eur. Pat. Appl., 140 pp.

CODEN: EPXKDW

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 151826	A1	19850821	EP 1984-201851	19841213
EP 151826	B1	19930331		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 87626	E	19930415	AT 1984-201851	19841213
ES 539281	A1	19870616	ES 1984-539281	19841231
AU 8537364	A1	19850912	AU 1985-37364	19850107
AU 573673	B2	19880616		
CA 1259609	A1	19890919	CA 1985-471589	19850107
DK 8500089	A	19850710	DK 1985-89	19850108
FI 8500079	A	19850710	FI 1985-79	19850108
FI 83867	B	19910531		
FI 83867	C	19910910		
NO 8500085	A	19850710	NO 1985-85	19850108
NO 160849	B	19890227		
NO 160849	C	19890607		
JP 60185777	A2	19850921	JP 1985-479	19850108
JP 07068240	B4	19950726		
HU 36471	A2	19850930	HU 1985-61	19850108
HU 200338	B	19900528		
ZA 8500187	A	19860827	ZA 1985-187	19850108
RO 90622	B3	19861210	RO 1985-117252	19850108
SU 1396964	A3	19880515	SU 1985-3836858	19850108
IL 74018	A1	19880831	IL 1985-74018	19850108
PL 145710	B1	19881031	PL 1985-251488	19850109
PRIORITY APPLN. INFO.:			US 1984-569369	A 19840109
			US 1984-671135	A 19841113
			EP 1984-201851	A 19841213

GI

L5 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB The title compds. I (Z-Z3 = CH, or one of Z-Z3 is N and the remainder are CH; Z4 = CH2, O, S, SO, SO2; R = alkyl, aryl, heteroaryl-, acyl-, hydroxy-, aryloxy, heteroaryloxy-, alkoxy-, arylthio-, carbonyl-, carboalkoxy-, cyano-, amino-, ureido-, thioureido-, or guanidinoalkyl, cycloalkyl, alkenyl, arylalkenyl; R1 = H, alkyl; R2 = H, alkyl, cycloalkyl, aryl, heteroaryl, aryl- or heteroarylalkyl), which were prepared, exhibited antihistaminic activity. Thus, a mixture of 2-(4-MeC6H4CH2NH)C6H4NH2 and Et 1-benzyl-4-piperidineacetimidate hydrochloride in MeOH was refluxed and NH3 was added to give benzimidazole II.

IT 99958-99-3P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and antihistaminic activity of)


RN 99958-99-3 CAPLUS

CN 1-Piperidineethanol, 4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl)methyl]-α-[(2-naphthalenyloxy)methyl]-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 99958-98-2

CMF C33 H34 F N3 O2




L5 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 144-62-7

CMF C2 H2 O4



L5 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1963:454886 CAPLUS  
 DOCUMENT NUMBER: 59:54886  
 ORIGINAL REFERENCE NO.: 59:10005a-e  
 TITLE: 4-(Indolylalkyl)-N-alkylpiperidines  
 INVENTOR(S): Gray, Allan Poe  
 PATENT ASSIGNEE(S): Irwin, Neisler and Co.  
 SOURCE: 28 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR M1693		19630311	FR	
GB 925429			GB	
US 3136770		1964	US	


PRIORITY APPLN. INFO.: 19600401

GI For diagram(s), see printed CA Issue.  
 AB 4-(Indolylalkyl)piperidines are treated with alkylating agents to give pyridinium salts, which are reduced with NaBH<sub>4</sub> and then with H(Pt) to give the title compds., which can be used as analgesics. Thus, a solution of 53 g. 4-(3-indolylethyl)pyridine in 200 ml. HOAc is hydrogenated over 1.2 g. Adams Pt catalyst at room temperature at 3.5 kg./cm.<sup>2</sup> 45 hrs., the catalyst filtered off, the filtrate concd. in vacuo, the residue taken up in H<sub>2</sub>O containing HCl, the solution washed with ether, and made alkaline; solidification of the oil that seps. gives 69% 4-(3-indolylethyl)piperidine (I), m. 162-3° (iso-PrOH); HCl salt m. 213-15° (decomposition, MeOH). A mixture of 125 g. I, 150 g. Na<sub>2</sub>CO<sub>3</sub> H<sub>2</sub>O, and 750 ml. iso-PrOH is refluxed, a solution of 102 g. Ph(CH<sub>2</sub>)<sub>2</sub>Br in 125 ml. iso-PrOH added dropwise, the mixture heated 16 hrs. and filtered hot, concentrated, and cooled, and the precipitate filtered off and recrystd. from EtOH to give 148 g. 4-(3-indolylethyl)-1-phenethylpiperidine (II), m. 129-30°; HCl salt m. 225-6° (decomposition, iso-PrOH); MeBr salt m. 233-4° (decomposition, EtOH); acetate m. 122-5° (iso-PrOH); maleate m. 103-6° (EtOAc MeOH). Similarly prepared are (m.p. given): 4-(3-indolylethyl)-1-(p-nitrophenethyl)piperidine, 173-5° (HCl salt m. 254-5°) (decomposition) (ether-iso-PrOH); 4-(3-indolylethyl)-1-benzylpiperidine, 91-2° (Skellysolve B) (HCl salt m. 192-3°) (EtOH); 4-(3-indolylethyl)-1-(p-aminophenethyl)piperidine-2HCl, 293° (decomposition) (EtOAc-MeOH); 4-(3-indolylethyl)-1-(β-hydroxyphenethyl)piperidine, 133-5° (EtOH) (HCl salt m. 193-4°) (EtOH-ether); 4-(3-indolylethyl)-1-phenethyl-Δ<sup>3</sup>-piperidine, 132-3° (C6H6-Skellysolve B) (HCl salt m. 179-80°); 4-(3-indolylethyl)-1-phenacylpiperidine, 173-4° (C6H6) (HCl salt m. 235-6°) (MeOH-ether); 4-(3-indolylethyl)-1-


L5 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1962:60534 CAPLUS  
 DOCUMENT NUMBER: 56:60534  
 ORIGINAL REFERENCE NO.: 56:11559h-1,11560a-e  
 TITLE: Catalytic hydrogenation of indolylethylpyridines. 4-(indolylethyl)-1-alkylpiperidines as potent analgesics  
 AUTHOR(S): Gray, Allan P.; Kraus, Harold  
 CORPORATE SOURCE: Irwin, Neisler & Co., Decatur, Ill.  
 SOURCE: Journal of Organic Chemistry (1961), 26, 3368-73  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable  
 OTHER SOURCE(S): CASREACT 56:60534

GI For diagram(s), see printed CA Issue.  
 AB Catalytic hydrogenation of indolylethylpyridine bases in acidic solns. gave the corresponding indolylethylpiperidines. These reacted with aryl substituted alkylating agents to give indolylethyl-1-alkylpiperidine derivs. (I). The same products were obtained by initial quaternization of the pyridine followed by hydrogenation under neutral conditions. Several of these compds. proved to be as effective as morphine in producing analgesia in animals. Thus, a solution of 53 g. 4-[2-(3-indolylethyl)pyridine in 200 ml. glacial AcOH was hydrogenated over 1.2 g. PtO<sub>2</sub> at room temperature and 50 lb./sq. in. Hydrogen absorption was slow, the calculated amount being absorbed in 45 hrs. The filtered solution was concentrated in vacuo to a thick, red oil which was taken up in dilute aqueous acid. The aqueous solution was washed with Et<sub>2</sub>O and made alkaline to precipitate an oil which solidified. The solution was recrystd. with C treatment from iso-PrOH to give 37.7 g. 4-[2-(3-indolylethyl)pyridine (II), m. 162-3°. A stirred mixture of 125 g. II, 150 g. Na<sub>2</sub>CO<sub>3</sub> H<sub>2</sub>O, and 750 ml. iso-PrOH was refluxed and a solution of 102 g. Ph(CH<sub>2</sub>)<sub>2</sub>Br in 125 ml. iso-PrOH added dropwise. Stirring and heating was continued 16 hrs. The hot reaction mixture was filtered, the filtrate was concentrated in vacuo to a smaller volume and cooled in an ice bath. Recrystn. of the resultant precipitate from EtOH gave 148 g. 4-[2-(3-indolylethyl)-1-phenethylpiperidine, m. 129-30° hydrochloride m. 225-6°. The following I were prepared (R, R', m.p., (m.p. of hydrochloride given): benzyl, H, 91-2°, 192-3° α-phenylpropyl, H, 110-12°, 180-1° β-hydroxyphenethyl, H, 133-5°, 193-4° phenacyl, H, 173-4°, 233-4° cinnamyl, H, 129-31°, --; phenoxyethyl, H, 102-3°, 170° β-hydroxy-γ-phenoxypropyl, H, 96-7°, 196-7° p-nitrophenethyl, H, 173-5°, 254-5° p-aminophenethyl, H, --, (di-HCl salt) 293° H, Me, 65-6°, 200-1° phenethyl, Me, --, 201-2° β-hydroxyphenethyl, Me, --, 193-5°. The following III were prepared (R, R', piperidine position, m.p., m.p. of hydrochloride given): H, 3-indolyl, 2, 189-1°, 218-19° γ-hydroxyphenethyl, 3-indolyl, 2, --, 1235° phenethyl, 1-indolyl, 4, --, 161-6° 3-indolylethyl, Ph, 4, 119-20°, 233-5°. The following IV were prepared (R, indole position, m.p. given): phenethyl, 3, 157-7.5° γ-phenylpropyl, 3, gradually above 65° phenoxyethyl, 3, 149-51° phenethyl, 1, 151-4°.


L5 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 (phenoxyethyl)piperidine, 102-3° (HCl salt m. 170°; MeBr salt m. 200-8°); 4-(3-indolylethyl)-1-(3-phenoxy-2-hydroxypropyl)piperidine, 96-7° (HCl salt m. 196-7°); 4-(1-methyl-3-indolylethyl)-1-phenethylpiperidine, (HCl salt m. 201-2°); 4-(1-methyl-3-indolylethyl)-1-(β-hydroxyphenethyl)piperidine-HCl, 193-5°; and 4-(1-indolylethyl)-1-phenethylpiperidine-HCl, 161-6°.  
 IT 95703-73-4, 1-Piperidineethanol, 4-(2-indol-3-ylethyl)-α-(phenoxyethyl)- 104878-12-8, 1-Piperidineethanol, 4-(2-indol-3-ylethyl)-α-(phenoxyethyl)-, hydrochloride (preparation of)  
 RN 95703-73-4 CAPLUS  
 CN 1-Piperidineethanol, 4-(2-indol-3-ylethyl)-α-(phenoxyethyl)- (7CI) (CA INDEX NAME)




RN 104878-12-8 CAPLUS  
 CN 1-Piperidineethanol, 4-(2-indol-3-ylethyl)-α-(phenoxyethyl)-, hydrochloride (7CI) (CA INDEX NAME)



L5 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 IT 95703-73-4, 1-Piperidineethanol, 4-(2-indol-3-ylethyl)-α-(phenoxyethyl)- 104878-12-8, 1-Piperidineethanol, 4-(2-indol-3-ylethyl)-α-(phenoxyethyl)-, hydrochloride (preparation of)  
 RN 95703-73-4 CAPLUS  
 CN 1-Piperidineethanol, 4-(2-indol-3-ylethyl)-α-(phenoxyethyl)- (7CI) (CA INDEX NAME)



RN 104878-12-8 CAPLUS  
 CN 1-Piperidineethanol, 4-(2-indol-3-ylethyl)-α-(phenoxyethyl)-, hydrochloride (7CI) (CA INDEX NAME)





```

7  8  9  10  11  12
ring nodes :
1  2  3  4  5  16
chain bonds :
1-10  3-7  7-8  8-9  8-11  11-12
ring bonds :
1-5  1-16  2-3  2-16  3-4  4-5
exact/norm bonds :
1-5  1-16  2-3  2-16  3-4  4-5  8-9  11-12
exact bonds :
1-10  3-7  7-8  8-11
isolated ring systems :
containing 1 :

```

G1:O,S

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 16:CLASS

L6 STRUCTURE UPLOADED

=> d

L6 HAS NO ANSWERS

L6 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l6 ful

FULL SEARCH INITIATED 17:25:26 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 715 TO ITERATE

100.0% PROCESSED 715 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L7 2 SEA SSS FUL L6

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1977:190642 CAPLUS

DOCUMENT NUMBER: 86:190642

TITLE: Polyglycidyl compounds containing N-heterocyclic

structure

INVENTOR(S): Habermeyer, Juergen; Batzer, Hans; Porret, Daniel

PATENT ASSIGNEE(S): Ciba-Geigy Corp., USA

SOURCE: U.S., 13 pp. Division of U.S. 3,900,493.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4001236	A	19770104	US 1975-588528	19750619
CH 581131	A	19761029	CH 1972-9528	19720623
US 3900493	A	19750819	US 1973-371449	19730619
ES 416144	A1	19760601	ES 1973-416144	19730622
IT 1003091	A	19760610	IT 1973-25749	19730622
US 4052366	A	19771004	US 1975-582041	19750529
US 3998837	A	19761221	US 1975-590550	19750626
US 3956309	A	19760511	US 1975-591678	19750630
US 4007199	A	19770208	US 1975-593916	19750707
US 4011235	A	19770308	US 1975-593801	19750707
			CH 1972-9528	A 19720623

PRIORITY APPLN. INFO.:

US 1973-371449 A3 19730613

CH 1973-5750 A 19730419

GI



AB The title compds., prepared by treating polyepoxides with N-heterocyclic compds., are treated with epichlorohydrin (I) to give polyglycidyl


compds. which, when mixed with dicarboxylic anhydrides, are easily cured at 60-160°. Thus, 5,5-dimethylhydantoin [77-71-4] was treated with 1,1'-methylenebis(3-glycidyl-5,5-dimethylhydantoin) [15336-85-3] in the presence of Me4NCl to give the heterocyclic compound [52213-60-2] (II). Treatment of II with I gave a resin having epoxide content 4.30 equivalent/kg.

Several similar compds. were also prepared. The resins were mixed with hexahydrophthalic anhydride and cured at 140-50° to give clear

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

PAGE 1-B



L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

transparent moldings.

IT 52213-62-4DP, reaction product with epichlorohydrin


52213-62-4P

RL: PREP (Preparation)


(preparation of)

RN 52213-62-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 3,3'-[1-methylethylidene]bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)]bis[dihydro-5,5-dimethyl-6-(1-methylethyl)- (9CI) (CA INDEX NAME)]




PAGE 1-A



PAGE 1-B

RN 52213-62-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 3,3'-[1-methylethylidene]bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)]bis[dihydro-5,5-dimethyl-6-(1-methylethyl)- (9CI) (CA INDEX NAME)]



PAGE 1-A

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1972:541586 CAPLUS

DOCUMENT NUMBER: 77:141586

TITLE: Hydantoin, uracil, and isocyanurate glycidyl acrylate

and methacrylate monomers and polymers

INVENTOR(S): Habermeyer, Juergen; Porret, Daniel; Leumann, Ernst

PATENT ASSIGNEE(S): Ciba-Geigy A.-G.

SOURCE: Ger. Offen., 58 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2201793	A	19720803	DE 1972-2201793	19720114
CH 542851	A	19731130	CH 1971-624	19710115
US 3808226	A	19740430	US 1972-217629	19720113
GB 1367207	A	19740918	GB 1972-1911	19720114
JP 55049577	B4	19801212	JP 1972-6556	19720114
FR 2122268	A5	19720825	FR 1972-1405	19720117
US 3894016	A	19750708	US 1974-433629	19740116

PRIORITY APPLN. INFO.:

CH 1971-8634 A 19710614

US 1972-217629 A3 19720113

AB Twety of the title acrylates and methacrylates were prepared and some were

homopolymd. to resins useful as surface coatings, molding powders, and casting resins. In an example, 258 g 1,3-diglycidyl-5,5-dimethylhydantoin, 3 g hydroquinone (I), and 147.7 g acrylic acid was heated 20 min at 100-22.deg.; 2 addnl. 1 g portions I were added and

after 90 min at 125-30.deg. there was obtained 1,3-bis(3-acryloxy-2-hydroxypropyl)-5,5-dimethylhydantoin (II) [36636-06-3]. II (100 parts) and 1.5 parts 50% cyclohexanone hydroperoxide was treated 2 hr at 80.deg. and 12 hr at 120.deg. in an Al mold to give hard plates of flexural strength 16.2-17.1 kg/mm2 and 4.9-5.2 mm (VSM 77103).

IT 38817-96-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 38817-96-8 CAPLUS

CN 2-Propenoic acid, 2-methyl-,

2-hydroxy-2-methyl-3-[(tetrahydro-3-[2-hydroxy-3-[(2-methyl-1-oxo-2-propenyl)oxy]propyl]-5,5-dimethyl-4-(1-methylethyl)-2,6-dioxo-1(2H)-pyrimidinyl]propyl ester (9CI) (CA INDEX NAME)]

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

